|
Status |
Public on Jan 11, 2020 |
Title |
Omipalisib Inhibits Esophageal Cancer Growth through PI3K/AKT/mTOR Signalling Pathway Disruption |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
Esophageal squamous cell carcinoma (OSCC) is a lethal digestive tract malignancy with limited effective interventions. This study aims to explore a new potential inhibitor on OSCC and investigate the underlying mechanisms. Based on a drug screen of an FDA-proven library consisting of 1404 compounds, we demonstrated that Omipalisib, a dual PI3K/mTOR inhibitor, markedly inhibited cell proliferation and colony formation in a panel of OSCC cell lines. Mechanistically, Omipalisib induced G0/G1 phase cell cycle arrest and apoptosis. Moreover, RNA-seq, KEGG and GSEA confirmed that the PI3K/mTOR signalling pathway is the primary target of Omipalisib in OSCC cells. Omipalisib treatment suppressed the PI3K/mTOR signalling pathway. Furthermore, Omipalisib exerted a significant antineoplastic effect on OSCC tumour xenografts in BALB/c nude mice without obvious side effects. The present study supports the rationale for using Omipalisib as a therapeutic approach for OSCC cases and suggests the potential clinical evaluation of this strategy.
|
|
|
Overall design |
In this study, we investigated the therapeutic effects and underlying mechanisms of Omipalisib in OSCC cells based on a screen of compound library.
|
|
|
Contributor(s) |
Zhu D, Dong J, Xu Y, Zhang X, Fu S, Liu W |
Citation(s) |
32804918 |
|
Submission date |
Jan 10, 2020 |
Last update date |
Sep 08, 2020 |
Contact name |
Dongshan Zhu |
E-mail(s) |
[email protected]
|
Phone |
13643720644
|
Organization name |
Jilin University First Hospital
|
Department |
thracic department
|
Street address |
71 Xinmin Street
|
City |
Changchun Jilin |
ZIP/Postal code |
130021 |
Country |
China |
|
|
Platforms (1) |
|
Samples (6)
|
|
Relations |
BioProject |
PRJNA600533 |
SRA |
SRP241240 |